The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Class 3 BRAF alterations predict poor immunotherapy outcomes in NSCLC
Alessandro Di Federico, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a retrospective study on class 2 and class 3 BRAF alterations in non-small cell lung cancer (NSCLC), which found that class 3 alterations were associated with a higher tumor mutational burden and poorer outcomes with immunotherapy. Mutations in genes such as STK11, CDKN1, and SMARCA4 were more frequent in tumors with class 3 alterations and were consistently associated with worse overall survival, suggesting that these tumors may have limited responsiveness to immunotherapy. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
